Compare the add-on effects in glycemic control and durability of sitagliptin and alfa-glucosidase inhibitor uncontrolled with metformin monotherapy.

Trial Profile

Compare the add-on effects in glycemic control and durability of sitagliptin and alfa-glucosidase inhibitor uncontrolled with metformin monotherapy.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 17 May 2016

At a glance

  • Drugs Alpha-glucosidase inhibitors (Primary) ; Sitagliptin (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top